CVS Health (CVS) Stock Forecast & Price Target

Q: What analysts cover CVS Health?

CVS Health has been rated by research analysts at Argus , Barclays , BMO Capital Markets , Cantor Fitzgerald , JPMorgan Chase & Co. , Leerink Partners , Piper Sandler , Robert W. Baird , Sanford C. Bernstein , UBS Group , and Weiss Ratings in the past 90 days.

$92.45 +2.06 (+2.28%)

Closing price 03:59 PM Eastern

Extended Trading

$92.44 -0.01 (-0.02%)

As of 07:54 PM Eastern

Compare

CVS Health - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
3

Buy
20

Based on 23 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 3 have given a hold rating, and 20 have given a buy rating for CVS.

Consensus Price Target

$107.80
16.60% Upside

According to the 23 analysts' twelve-month price targets for CVS Health, the average price target is $107.80. The highest price target for CVS is $123.00, while the lowest price target for CVS is $90.00. The average price target represents a forecasted upside of 16.60% from the current price of $92.45.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVS Analyst Ratings Over Time

Type	Current Forecast 10/15/25 to 10/15/26	1 Month Ago 9/15/25 to 9/15/26	3 Months Ago 7/17/25 to 7/17/26	1 Year Ago 10/15/24 to 10/15/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	20 Buy rating(s)	22 Buy rating(s)	21 Buy rating(s)	18 Buy rating(s)
Hold	3 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$107.80	$107.24	$105.38	$81.62
Forecasted Upside	16.60% Upside	13.50% Upside	-1.85% Downside	1.07% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CVS Health Stock vs. The Competition

Type	CVS Health	Healthcare Companies	Broader Market
Consensus Rating Score	2.87	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	17.28% Upside	1,132.49% Upside	18.91% Upside
News Sentiment Rating	Positive News See Recent CVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/12/2026	Leerink Partners 3 of 5 stars	Michael Cherny 4 of 5 stars	Lower Target	Outperform	$119.00 ➝ $112.00	+30.01%
10/9/2026	Weiss Ratings 3 of 5 stars		Downgrade	Buy (B-) ➝ Hold (C+)
10/9/2026	Cantor Fitzgerald 5 of 5 stars	Sarah James 3 of 5 stars	Reiterated Rating	Neutral
9/22/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Kevin Caliendo Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy
9/9/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$112.00	+18.06%
9/9/2026	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Jessica Tassan Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$112.00	+18.06%
9/9/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Lance Wilkes Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform	$112.00	+19.98%
8/19/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	Steve Silver Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$104.00 ➝ $114.00	+19.92%
8/12/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lisa Gill Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$111.00 ➝ $118.00	+26.09%
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Ha Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$107.00	+10.60%
Get the Latest News and Ratings for CVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CVS Health and its competitors with MarketBeat's FREE daily newsletter.
8/6/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Andrew Mok Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$106.00 ➝ $108.00	+8.83%
7/14/2026	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	David MacDonald Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$108.00 ➝ $118.00	+11.26%
7/13/2026	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Stephen Baxter Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$103.00 ➝ $123.00	+18.10%
7/9/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Ben Hendrix Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$107.00 ➝ $113.00	+8.33%
7/6/2026	HSBC Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Hold	$103.00	+0.72%
6/22/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Allen Lutz Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$100.00 ➝ $110.00	+7.54%
6/8/2026	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Ann Hynes Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$110.00 ➝ $115.00	+20.18%
6/4/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Erin Wright Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$106.00 ➝ $111.00	+21.17%
5/11/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Charles Rhyee Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$105.00 ➝ $110.00	+20.18%
5/7/2026	DA Davidson Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Buy	$80.00 ➝ $100.00	+14.05%
5/7/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Buy	$88.00 ➝ $92.00	+4.93%
3/2/2026	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Outperform	$100.00 ➝ $97.00	+20.86%
2/12/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Scott Fidel Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$95.00 ➝ $97.00	+23.39%
10/31/2025	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target		$75.00 ➝ $90.00	+15.20%
10/30/2025	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target		$92.00 ➝ $98.00	+25.44%
10/30/2025	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Elizabeth Anderson Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Outperform	$85.00 ➝ $95.00	+22.55%
9/8/2025	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Strong-Buy ➝ Hold
7/16/2025	Bernstein Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Market Perform	$78.00 ➝ $72.00	+12.86%
1/30/2025	Edward Jones Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Hold ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:00 PM ET.

Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 12, 2026. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

CVS Health Co. recently reported strong third-quarter earnings, beating analyst expectations with an actual earnings per share of $2.58 compared to the consensus estimate of $1.87, demonstrating the company's ability to outperform market forecasts and drive shareholder value through operational efficiency.
The stock is currently trading at $87.93, which is significantly below the consensus price target of $107.24 set by Wall Street analysts, suggesting a potential upside of approximately 22% for investors who believe the market is currently undervaluing the company's turnaround efforts.
CVS Health Co. has raised its full-year 2026 earnings per share guidance to a range of $7.90 to $8.10, which is well above the previous consensus estimate of $7.44, indicating management's confidence in sustained revenue growth and cost management throughout the remainder of the fiscal year.
The company offers a dividend yield of 3.03%, providing a steady income stream for investors, which is particularly attractive given the stock's recent volatility and its position near the lower end of its 52-week trading range between $69.51 and $110.68.
Recent institutional activity shows positive momentum, with firms like Farther Finance Advisors LLC increasing their holdings by 30.6% in the third quarter, signaling that professional investors are accumulating shares and potentially identifying a long-term value opportunity in the healthcare sector.

CVS Health
Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

CVS Health Co. faces significant regulatory and reputational risk following the initiation of an investigation by Kahn Swick & Foti, LLC into the company's officers and directors, which could lead to legal costs, management distraction, and potential financial liabilities that are not yet reflected in the current stock price.
The company's Aetna unit received weaker-than-expected Medicare Advantage star ratings for 2027, with TD Cowen estimating this could result in a $0.41 hit to earnings per share, highlighting ongoing challenges in maintaining high-quality clinical performance and member satisfaction in a competitive insurance market.
Despite recent earnings beats, the stock has experienced a sharp retreat from its summer highs, with a gap down of 10.7% observed in August 2026, suggesting that investors may be pricing in structural headwinds such as increasing medical costs and reimbursement pressures that could limit future profitability.
CVS Health Co. carries a debt-to-equity ratio of 0.74 and a current ratio of 0.87, indicating that the company has more short-term liabilities than current assets, which could constrain its financial flexibility and ability to invest in growth initiatives during periods of economic uncertainty.
Recent insider selling activity, including large block sales by Director Larry Robbins in May 2026, may signal a lack of confidence among company insiders regarding the stock's near-term valuation, potentially dampening retail investor sentiment and limiting upward price momentum.

CVS Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $107.80, with a high forecast of $123.00 and a low forecast of $90.00.

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last twelve months. There are currently 3 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CVS shares.

According to analysts, CVS Health's stock has a predicted upside of 16.60% based on their 12-month stock forecasts.

Over the previous 90 days, CVS Health's stock had 2 upgrades and 1 downgrade by analysts.

CVS Health has been rated by research analysts at Argus, Barclays, BMO Capital Markets, Cantor Fitzgerald, JPMorgan Chase & Co., Leerink Partners, Piper Sandler, Robert W. Baird, Sanford C. Bernstein, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like CVS Health more than other "healthcare" companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how CVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With CVS Health Recommendations

MarketBeat monitors more than a dozen sources for CVS Health analyst ratings, with the most recent rating issued on 10/12/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CVS Health (CVS) Stock Forecast & Price Target